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Immune-based anti-cancer strategies combined with radiation therapy (RT) are actively 
being investigated but many questions remain, such as the ideal treatment scheme and 
whether a potent immune response can be generated both locally and systemically. In this 
context, tumor-associated tertiary lymphoid structures (TLS) have become a subject of 
research. While TLS are present in several types of cancer with strong similarities, they 
are especially relevant in medullary breast carcinoma (MBC). This suggests that MBC 
patients are ideally suited for investigating this question and may benefit from adapted 
therapeutic options. As RT is a corner-stone of MBC treatment, investigating interactions 
between RT and TLS composition is also clinically relevant. We thus first characterized 
the lymphoid structures associated with MBC in a patient case report and demonstrated 
that they closely resemble the TLS observed in a genetical mouse model. In this model, 
we quantitatively and qualitatively investigated the cellular composition of the tumor- 
associated TLS. Finally, we investigated TLS regulation after hypo-fractionated RT and 
showed that RT induced their acute and transient depletion, followed by a restoration 
phase. This study is the first work to bring a comprehensive and timely characterization 
of tumor-associated TLS in basal conditions and after RT. It highlights cellular targets 
(i.e., Tregs) that could be selectively modulated in subsequent studies to optimize 
anti-tumor immune response. The study of TLS modulation is worth further investigation 
in the context of RT and personalized medicine.
Keywords: medullary breast carcinoma, radiation therapy, tertiary lymphoid structures, microenvironment, 
KP model
inTrODUcTiOn
Medullary breast carcinoma (MBC) is a unique and curious subtype of infiltrating ductal carcinoma 
first described in 1945 (1). According to histological risk-grading procedures, it is classified as 
medium to high grade and often exhibits basal-like biological features and a triple negative molecular 
status. In 1977, Ridolfi et al. published a study with 10 years longitudinal follow-up on MBC and 
2Boivin et al. TLS Contribution to RT
Frontiers in Oncology | www.frontiersin.org July 2018 | Volume 8 | Article 256
showed that only 13.5% of MBC patients had LN metastasis. 
From this seminal study, it appeared that MBC was less prone 
to metastatic development and consequently had a relatively 
good prognosis, despite its epithelial grade and molecular profile 
status. It was speculated early on that this paradox was linked 
to the typical lymphoplasmatic intra-tumor infiltration and/or 
the presence of tertiary lymphoid structures (TLS) at the vicinity 
of MBC (2). However, recent work has challenged this notion of 
a favorable prognosis (3) and radio-chemotherapy remains the 
standard of care for these patients (4), at the costly risk, however, 
of over-treating young patients.
In the current increasing effort to understand and harness 
anti-tumor immune responses (5–9), TLS have recently become a 
focal point for research. The presence of TLS has indeed been cor-
related with a good prognosis value in various primary tumors, 
such as triple negative breast carcinoma, colorectal cancer, gastric 
cancer, non-small cell lung carcinoma, melanoma, oral squamous 
cell carcinoma, pancreatic carcinoma, renal cell carcinoma, and 
correlated with a negative prognostic value in hepatocellular 
cancer (10). Further work also identified biomarkers that cor-
related with TLS quality and prognosis value such as DC-Lamp 
high or CD83+ that identify mature dendritic cells; PNAd+ high 
endothelium venules with the presence of CD3 T cells and expres-
sion of the CXCL13 cytokine. Although these biomarkers appear 
to be a key for TLS formation, they are not specific to a primary 
tumor type and can be found across breast, lung, and colon 
carcinoma (11, 12). More recently, an extensive characterization 
of gene expression in tumors associated with TLS has been per-
formed and enhanced our understanding about TLS formation 
(10). Modulation of TLS was suggested to be an attractive option 
to improve anti-tumor immunity in situ or enhance the efficacy 
of current immunomodulators, but these novel options have not 
yet been translated into the clinical setting.
In addition, understanding how TLS are modulated after 
anti-cancer treatment is still needed but the experimental 
models available to study TLS function are limited. Although the 
presence of TLS was reported in a pre-clinical mouse model of 
melanoma (13) and correlated with extended survival in another 
pancreatic cancer model (14), the KrasLox-STOP-LOX-G12D/WT; p53Flox/Flox 
(KP) mouse model of lung adenocarcinoma is so far the only 
model where functionality of TLS was suggested (15). In KP/
OVA mice, anti-tumor-specific adoptively transferred T-OVA 
cells were shown to proliferate in TLS. Therefore, this model is 
interesting in terms of characterizing TLS and investigating their 
response to an anti-cancer treatment such as radiation therapy 
(RT). RT is able to modulate tumor immune infiltrate (16–18) as: 
it induces immunogenic tumor cell death that favors tumor anti-
gen release and processing; it alters the local cytokine/chemokine 
balance to favor antigen processing, DC maturation, and immune 
cell functionality; and it reorganizes the microenvironment by 
depleting/recruiting/polarizing adequate immune cells locally 
(19). However, to our knowledge, no studies have investigated 
the response of TLS to radiation in order to establish relevant 
schemes of treatment applicable to this well-defined group of 
patients.
The goal of this work was to provide new insights to the cellular 
composition of TLS and their contribution to anti-tumor immune 
infiltration. To do this, we first highlight two histo-pathologically 
related cases of basal breast cancer which differ by the presence of 
proliferating TLS versus nonspecific inert lymphoid aggregates. 
Then to further investigate TLS composition, we used KP mice 
which are the only autochthonous mouse model known to dis-
play functional TLS to date (15). Finally, we assessed combined 
contribution of TLS and tumors to immune infiltrate during the 
time course of RT.
MaTerials anD MeThODs
human histopathological samples
Surgical samples of two patients with breast cancer were analyzed 
after HE staining by histopathology. Tumors were located inside 
the mammary gland away from any lymph node. For diagnosis 
of MBC and basal carcinoma, characterization of molecular 
subtypes was performed using routine staining (ER, PR, HER2, 
Ecad, cytokeratin, and Ki-67). In addition, immune infiltrates 
were analyzed using CD4, CD8, CD20, PD1, and FoxP3. The 
number of CD8 and CD4 positive cells was quantified under 
microscope. The two patients were treated at “Hospital Riviera 
group,” VD Switzerland. They signed an informed consent and 
agreed to the use of their clinical data and pathology into a 
scientific publication.
human immunohistochemistry analysis
For the multiplexed staining, 4  µm formalin-fixed paraffin-
embedded sections from breast tumor were stained by automated 
immunostainer (DISCOVERY ULTRA, Ventana Roche). Heat-
induced antigen retrieval in EDTA buffer (pH 8.0) for 32  min 
at 98°C was performed. The blocking step was followed by 
incubation with Protein block buffer (Dako) for 8 min. Staining 
was performed in consecutive round, each round consisting of 
antigen retrieval, blocking, primary antibody, secondary HRP-
labeled antibody, tyramide signal amplification (TSA) reagents, 
and antibodies denaturation. Then the primary antibodies were 
incubated at room temperature for 60 min, monoclonal mouse 
anti-human PD1 antibody (BioSB, NAT-105, 1:500), rabbit mon-
oclonal anti-human FoxP3 (Abcam, SP97, 1:50), mouse mono-
clonal antibody anti-pan Cytokeratin (1:250, Clone AE1/AE3, 
Dako), and rabbit monoclonal antibody anti-CD8 (1:100, Clone 
SP16, ThermoFisher Scientific). The signal was revealed with 
DISCOVERY OmniMap anti-rabbit HRP (Ventana, #760-4311) 
or anti-mouse HRP (Ventana, #760-4310) that was incubated 
for 12 min. Next, TSA amplification quality controlled reagents 
were added: TSA Cyanine 3 (NEL744B001KT, PerkinElmer), 
Discovery Cy5 kit (Ventana, #760-238), Discovery RED610 kit 
(Ventana, #760-245), and Discovery FAM kit (Ventana, #760-
243). The nuclei were visualized with Spectral DAPI (Perkin 
elmer, FP1490, 1:10). The images were acquired using the Vectra 
3.0 (Perkin Elmer) automated quantitative pathology imaging 
system at 20× magnification.
Mouse Model With Tls
KrasLox-STOP-LOX-G12D/WT and p53FL ox/FLox mice in a C57BL6/J back-
ground purchased from the Jackson Laboratory, bred to obtain 
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KrasLox-STOP-LOX-G12D/WT; p53FLox/FLox (KP) mice and kindly provided 
by E. Meylan’s laboratory (EPFL-Lausanne). All mouse experi-
ments were performed in accordance with Swiss regulations 
under the license numbers VD2920 and VD3242.
radiotherapy of KP Mice
KP tumors were initiated upon infection of lung epithelial cells 
with a lentiviral vector delivering Cre recombinase to activate 
oncogenic KrasG12D and delete p53 (20). 13- to 16-week-old mice 
were infected intratracheally with 3,000 Cre-active lentiviral 
units. During the follow-up period, tumor volume was monitored 
once every 2 weeks starting from 14 weeks post lentiviral instilla-
tion. Mice were imaged using the X-rad 225CX irradiator under 
isoflurane anesthesia. At dedicated time points, mice underwent 
RT with a 20 mm2 collimator, optimal for whole lung irradiation 
at (13 mA, 3 mm Cu filter, 225 keV) 11.7 Gy with a single dose 
delivered in 256 s.
histological and apoptosis analysis
Tertiary lymphoid structures were quantified in non-irradiated 
mice at 7, 15, and 20  weeks post-instillation. Tumor apoptosis 
was evaluated at 20 weeks post instillation. The radiation-induced 
impact on the TLS was monitored 20  weeks post instillation, 
on mice sampled 2 h, 2 days, and 14 days post-RT. Lungs were 
gently insufflated with 0.5 mL of 50% PBS-50% OCT (Cell-Path 
ref 81-0771-00) via the trachea using an I.V. surflo catheter (ref 
SR + OX2225C1). Lobes were subsequently separated and OCT-
frozen on dry ice. 20 sections of 6 µm were cut at different depths 
and were HE stained or stained with cleaved caspase 3 antibody 
for apoptosis detection (asp175, cell signaling). Images were 
obtained with upright microscope Axio Imager Z1 motorized 
and analyzed with Zen Zeiss blue software.
Flow cytometry and histological control
Mice were sampled 36 h, 14 days, and 56 days post-RT and tumors 
were collected and analyzed by flow cytometry as described 
previously (21) including gating strategy and list of antibodies. 
A LSRII SORP flow cytometer was used for acquisition. The qual-
ity of the tumor dissection was assessed by histology as described 
in the previous paragraph.
statistical analysis
All results are represented as mean ±  SEM. Analysis was per-
formed using Mann–Whitney test using Prism 6 software. For 
Flow cytometry analysis, a minimum of 12–25 tumors per group 
were analyzed (coming from 4 mice minimum).
resUlTs
Medullary Breast carcinoma Display Tls
Breast cancer classification according to histo-pathological and 
molecular subtypes is a main diagnosis criterion and defines 
treatment strategy. In this study, we investigated two carcinomas 
from breast cancer patients: patient 1 was a triple negative sub-
type with basal carcinoma features (Figures 1A–D); patient 2 was 
HER2+, PR−, and ER− with characteristics of basal carcinoma 
(Figures 1K–N). Tumors from patient 1 and 2 had a proliferative 
index of 30 and 5%, respectively (Figures 1E,O). Upon examina-
tion, both patients displayed immune infiltration, but we noticed 
major differences in the organization and structures of the 
immune aggregates. Whereas in patient 1 >30% of the tumor area 
composed of well-organized TLS, patient 2 had discrete spots of 
immune aggregates located near the tumors in a non-organized 
manner.
In patient 1, the TLS were defined by the presence of a typical 
germinal center, showing T/B cell organization (Figures 1F–H). 
In addition, their proliferation index measured by Ki67 reached 
30%, while aggregates in patient 2 (Figures 1P–R) had no local 
proliferation (Figures  1E,O). Although both tumors displayed 
important peritumoral CD8+ T  cells (Figures  1H,R,S), only 
patient 1 had significant intratumoral CD8+ infiltration.
Finally, patient 1 had significant peri-tumoral infiltration in 
both PD1+ cells and FoxP3+ cells (Figure 1I), whereas PD1+ 
cells were absent in patient 2 (Figure 1S). Intra-tumoral quantifi-
cation of CD8 and CD4 positive cells shows massive infiltration of 
CD8 and CD4 in patient 1 as compared to patient 2 (Figure 1T).
From the pathologist’s point of view, patient 1 displayed all of 
Ridolfi’s criteria (syncytial growth pattern in >75% of tumor area, 
tumor circumscription in a large capsulae, absence of intraductal 
component, large lymphoplasmatic infiltration, high mitotic 
rate, and poorly differentiated nuclear grade) and was classified 
as typical MBC.
Hereafter, we characterize the contribution of the TLS to the 
immune infiltrate and their response to radiation.
in KP Mice, Tls Occur after Tumor 
establishment and Display common 
Features With Tls Observed in MBc
To investigate the contribution of TLS in the tumor micro-
environment and their response to radiotherapy, we used KP 
mice in which tumors are associated with TLS. First, the number 
of tumors and the TLS per  section was quantified at different 
time points (Figure  2). In KP mice, the number of tumors is 
determined by initial lentivirus titration, therefore, the number 
of tumors inside a mouse is stable over time while differentiation 
grade and size tend to worsen as the tumors grow. We found 2.66 
tumors per mouse at W7 post-cre instillation, 4 at W15, and 9.3 
at W20. This increase over time mostly reflects the increased 
probability to cut through tumor tissue as they increase in size. 
We computed the corresponding TLS/tumor ratio over the time 
course of the experiment and found 0 TLS at W7; 0.58 TLS/tumor 
at W15, and 0.135 TLS/tumors at W20. Interestingly, in bigger 
tumors, we observed a tendency to lose TLS shape suggesting a 
mechanical or spatial constraint triggered by the tumor over the 
TLS. The TLS in the KP model never display external capsulae, 
as opposed to those observed in general in MBC patient. They 
were eventually contoured by a crown of CD163+ Ecadh+ cells 
(Figure 2C, 1). The TLS proliferation rate was assessed by Ki67 
staining (Figure 2C, 2) and shows a proliferation index compa-
rable to what was seen in patient 1. They did not systematically 
display germinal centers. B cells were always the most prevalent 
cell subtype and CXCL13 was detected in TLS (Figure  2C, 3); 
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FigUre 1 | Immune infiltrate in MBC (patient 1, P1) and basal breast carcinoma (patient 2, P2). Serial histological samples of P1 and P2 were stained with routine 
markers. Stainings showed the following repartition: estrogen receptor [(a–K) ER: P1−, P2−], progesterone receptor [(B–l) PR: P1−, P2−], human epidermal 
growth factor 2 [(c–M) HER2: P1−, P2+], Ecadherin [(D–n) Ecadh: P1+, P2+], P1−, P2−], and Ki67 [(e–O): P1 30% in tumor and tertiary lymphoid structures 
(TLS); P2 5% in tumor and 0% in immune aggregates]. Additional staining with non-routine markers was performed. They allowed characterization of TLS in P1 but 
not in P2: B cells [CD20 (F–P) P1 germinal center, P2 scarce cells], CD4 T cells [CD4 (g–Q) P1: present in all compartments; P2: non organized], CD8 T cells [CD8 
(h–r) P1: restricted to the TLS periphery and invading the tumor; P2: rare in the aggregates and absent in the tumor]. IF recapitulating the key immune 
components, including PD1, FoxP3 CD8, and tumor cytokeratine+ are shown in (i) and (s). PD1+ cells are absent in P2. (T) Intra-tumoral number of CD8 and CD4 
cells in P1 and P2.
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Lymphatic vessels, determined by the triple positive staining of 
CD31, Prox1, and Lyve1, were systematically associated with the 
TLS (Figure  2C, 4). We observed possible molecular crosstalk 
between TLS and tumors correlated with CXCR4 and SDF-1 
expression (Figure 2C, 5) and we observed pictures of TLS sur-
rounded by tumors (Figure 2C, 6).
Tumors With Tls are associated  
With increased Tumor apoptosis
Cleaved caspase 3 staining was performed on well established 
KP tumors in combination with EpCam (tumor cells) and 
CD45 (Pan-immune cells) or CD3 (T cells) and B220 (B cells). 
Independently from the presence of TLS, we found 86.7% of 
cleaved caspase 3+ signal was associated with tumor cells, 10.5% 
with immune cells (p <  0,0001), and 2.75% with unidentified 
stromal cells (p <  0.0001). Based on analysis of 15 tumors, we 
never found apoptotic lymphocytes in the tumor compartment. 
KP mice were divided into two groups, depending on the pres-
ence or absence of spatially related TLS (Figure 3B) and analyzed 
for tumor apoptosis using cleaved caspase3 immunostaining. 
The tumors associated with TLS presence showed four times fold 
increase in intra-tumor apoptosis (p <  0.001, Figure  3C) than 
the tumors without TLS. However, this increase was not corre-
lated with increased CD3 T cell (Figure 3C) infiltration or with 
increased B220 B cells (Figure 3C). These results suggest that the 
TLS presence is associated with increased intra-tumor cell death 
and this seems independent from quantitative T/B  cells tumor 
infiltration.
Tls size is reduced by rT
We next thought to modulate TLS presence and function with 
irradiation. 2 hours post radiation, we measured 8.7 times more 
cleaved caspase 3 cells in irradiated TLS per surface unit (p < 0.05 
Figures 4A,B). This increase was still significant 14 days post-RT. 
This increase in apoptosis was associated with a transient five 
times size reduction of TLS (p < 0.001, Figure 4C), normalized 
14 days post-RT. B cells absolute quantification within TLS was 
not monitorable because their concentration was too important. 
However, we found 72% significant reduction of total CD3 in TLS 
(Figure 4C). This reduction was no longer significant when CD3 
amount was normalized by TLS’ size, suggesting the morphol-
ogy of TLS directly correlates with the inner amount of T cells 
(Figure 4C). In tumors, we observed a 30% reduction (p < 0.01) 
of the CD3 T cells prevalence, suggesting the impact of RT on 
T  cells is more important within TLS (Figure  4C). However, 
because there is no possibility to extract T cells separately from 
tumors and TLS, we could not perform a standard radiosensitiv-
ity assay.
Macro-Dissected Tumors analyzed  
by Flow cytometry contains Tls
Before analyzing the intra-tumoral immune compartment of 
the  KP tumors by flow cytometry, we performed histological 
analyses on matched macro-dissected tumors. Our results showed 
that excised tumors contained TLS un-dissociable from the tumor 
core, meaning that the immune composition monitored by flow 
cytometry reflected both intra-tumor and the TLS components 
(Figure 5).
Immunofluorescence showed that Ly6G+ granulocytes were 
the main intra-tumoral CD45+ type of cell, whereas only few 
granulocytes were found in TLS (Figure 5A). CD68+ and CD11c+ 
myeloid cells (i.e., macrophages, dendritic cells, and monocytes) 
were found both in tumors and the TLS (Figure 5B). Although 
these markers are not sufficient to differentiate macrophages 
from DCs, CD68+, and CD11c+ cells had different morphology 
in tissue sections. They were large, round, and isolated in tumors 
A B
C D
FigUre 2 | Tertiary lymphoid structures (TLS) appear after tumor onset are maintained during disease progression and share common features with TLS in MBC. 
(a) Full KP lung section H&E stained. TLS are shown by red arrows, they are located around bronchus. Analysis on serial sections is required for proper TLS 
detection that can be present in one section and absent in 50 µm further. Green arrow showed the area of macro-dissected tumor used for flow cytometry. (B) KP 
lungs were sampled at 7, (timing of tumor occurrence), 15, and 20 weeks (final stage) post-cre installation. Tumor and TLS quantification were performed based on 
H&E staining similar to (a). TLS appeared after tumors’ onset. (c) Representative images are shown and illustrate common properties of TLS from KP and MBC 
such as the presence of germinal center and organizational features (1), 30% of proliferation (2). Additional stainings were performed. They show expression of 
CXCL13 chemokine (3), down left corner positive signal comes from the tumor (T), presence of Prox1+ Lyve1+ CD31+ lymphatic vessels (4). Picture 5 shows 
presence of aligned CXCR4+ cells in between TLS and tumor T. Picture 6 shows TLS engulfed by the tumor. Common features of KP versus MBC TLS are 
summarized in table (D).
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FigUre 3 | Presence of tertiary lymphoid structures (TLS) near tumors is correlated with tumor apoptosis, independently from quantitative B or T cell infiltration. 
Cleaved Caspase3 co-stainings with CD45 (immune), EpCap (tumor), CD3 (T cells) and B220 (B cells) apoptotic cells are mostly tumour cells (a). Control tumors 
with or without TLS were stained to assess wether the immune contexture correlates with apoptosis (White bands delineate tumors) (B). Quantification per unit 
surface and T/B cell ratio is shown is (c).
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C
FigUre 4 | Radiation therapy (RT) increases tertiary lymphoid structures (TLS) apoptosis and their transient depletion. Apoptosis quantification measured by 
cleaved caspase 3 in TLS in control of KP TLS, 2 h and 14 days post-RT. TLS size was measured with Zen Zeiss software (a). Quantification per surface unit is 
showed in (B). The prevalence of CD3+ T cells was assessed in TLS and tumours to evaluate intrinsic response to RT of those cells in different compartments (c).
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while TLS images suggesting reticular organization (Figure 5B) 
that may correspond to dendritic cells. The number of granu-
locytes per surface unit in tumors was 10 times higher than in 
TLS (Figure 5C). On the contrary, surface density of CD68 and 
CD11c+ cells was 2.5 higher in TLS than in tumor (Figure 5C). 
Next, we found that histological number per surface unit of intra-
tumor granulocytes was 45 times higher than B cells; at the same 
time, the surface of TLS was in average 12 times smaller than 
the surface of tumors (Figure 5E). When histological data were 
compared with flow cytometry, we could not confirm this differ-
ence and found a balanced number of B cells, CD11B high and 
intermediary granulocytes (Figure 5F). This discrepancy, taking 
into account the tumor/TLS size difference, suggests TLS contri-
bution to the immune compartment analyzed by flow cytometry 
is major. As granulocytes were mainly found in tumors and B cells 
mainly in TLS, we used granulocytes as a tumor biomarker and 
B cells as a TLS biomarker, and postulated that the flow cytometry 
analysis of macro-dissected tumors was including TLS.
Tls-related immune Modification  
after rT
As transient TLS reduction in size was shown after irradiation 
(Figure 4), we used it to validate the TLS contribution in the flow 
cytometry data of macro-dissected tumors. We used granulocytes 
as surrogate/biomarker of total immune compartment in tumors 
and B  cells as surrogate/biomarker of TLS, we first quantified 
histologically their variation induced by RT 2 h treatment. We 
found no changes at these endpoints in the tumor restricted area 
(Figure 6A), suggesting B cells as opposed to T cells (Figure 4), 
tolerated radiation in the tumor bed. Opposingly, flow cytom-
etry analysis showed a diminished B  cells/granulocytes ratio 
AB C
D E F
FigUre 5 | Histological and flow cytometry analysis correlation highlights granulocytes as biomarker of intra-tumor immune compartment and B cells as biomarker 
of tertiary lymphoid structures (TLS). Macro-dissected tumor H&E shows presence of TLS in samples. Granulocytes are almost absent in TLS and very abundant in 
tumors (a). CD68 and CD11c+ cells that include macrophages, monocytes, and DCs, but not granulocytes, are present in both compartments but display different 
morphological features (B). Tumor versus TLS quantification for CD68, CD11c, or granulocytes is shown in (c). Granulocytes are histologically much more prevalent 
than B cells in the tumor compartment (D). Size histological comparison of TLS and tumors is shown in (e). Strong prevalence of B cells obtained by Flow 
Cytometry analysis suggests TLS are also analysed with this method (F).
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by 3.7-fold with a return to basal level 14 and 56 days post-RT 
(Figure 6B). Correlated with results from Figure 4, this suggests 
TLS importantly contribute to the immune signature obtained 
from excised tumors. Granulocyte proportion was enhanced at 
36 h and then returned to basal level (Figure 6C). 36 h post-RT, 
B  cell proportion was reduced by 35% (p <  0.05, Figure  6C), 
T cells by 30% (p <  0.05, Figure 6C), and CD4T cells by 37% 
(p < 0.05, Figure 6B). Total T cells were reduced: among CD4+ 
T  cells, FoxP3 expressing Treg displayed a 60% reduction 
(p <  0,001, Figure  6C), while CD8 and CD4 non-Treg reduc-
tion was non-significant (Figure 6C), although a trend toward a 
decrease was observed. 14 and 56 days post-RT, to the exception 
of Tregs that showed a transient increase (+200%, p =  0.0001, 
Figure 6C), all variations in cell proportion returned to normal 
AC
D
B
FigUre 6 | Flow cytometry analysis confirms transient depletion of tertiary lymphoid structures (TLS) following RT. (a) The B cells/granulocyte ratio confirms with 
histological analysis of the TLS depletion (B). Tumor+ TLS lymphoid and granulocytes variations are presented in % of whole immune cells analyzed after 
macrodissection (c). T/B cells, CD8/Tregs, and CD4/CD8 ratio (D). Numeration of CD103 positive cells amongst CD8 cells (e).
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consistently with histological normalization of the TLS morphol-
ogy. In contrast to the B cell/granulocyte ratio, the inter-lymphoid 
ratio remained stable at early endpoint post-RT (Figure  6D) 
suggesting subpopulation among lymphoid cells responded in a 
common way to radiation. However, during the restoration phase 
of the TLS, CD8 repopulation was significantly counterbalanced 
by Tregs enrichment 14 days post-RT (Figure 6D) but associated 
with enrichment of CD103 positive cells among CD8 cells at late 
time point (Figure 6E).
DiscUssiOn
We used two case reports to highlight a major difference in 
immune infiltration within two basal breast carcinomas in 
order to illustrate the need for characterization of peri-tumoral 
immune contexture as these markers are not routinely performed 
in the clinic. While in MBC patient 1, the TLS are composed of 
locally proliferating lymphocytes organized around germinal 
centers, in patient 2 common aspecific aggregates are composed 
of non-proliferative recruited lymphocytes. These two sources 
of lymphocytes might not infiltrate tumors nor respond to 
loco-regional treatment the same way. This question is highly 
relevant for radio-oncologists as the TLS might contain potent 
lymphoid precursors that could be modulated (activated or 
depleted) by irradiation. Then, we used an experimental model 
with functional TLS (KP mice) to investigate the response of TLS 
to RT. Correlating histological analysis and previously established 
(21) flow cytometry method, we developed a semi-quantitative 
and qualitative analysis of TLS composition and assessed their 
response to RT. Main findings showed (1) increased apoptosis 
in tumors associated with TLS; (2) confirmed B cells as the main 
biomarker of TLS in patients and KP model; (3) highlighted TLS 
sensitivity to RT in  vivo; and (4) highlighted plasticity of TLS 
and their reappearance 14 days post-RT, providing a window of 
opportunity to optimize their function. Our results are a first step 
toward a comprehensive characterization of the composition of 
TLS after RT. In the era of immunotherapy combined with RT, 
TLS might be the next attractive target.
Investigating tumor physiology through its micro- 
environmental biology is an attractive angle for treatment 
optimization. Understanding the micro-environmental imprint 
and its potential stereotypical response to classical anti-cancer 
strategies may help to define broader therapeutic combination 
options which could be less resistant (22) and consistent with 
the increasingly common paradigm of “personalizing medicine.” 
Indeed, some micro-environmental characteristics are rare within 
a subgroup of defined specific tumor patients but may be studied 
and better understood if present in other more frequent primary 
tumor subtypes. In this context, TLS have shown a common 
physiological pattern, which is independent from the primary 
tumor subtype/organs and may stimulate common strategies 
applicable to various cancers (10, 23). Our study highlights the 
relevance of TLS and show several similarities between the TLS 
located in MBC patients and in the experimental KP mice. They 
both include about 30% lymphoid proliferative rate; presence of 
germinal centers with B cells as a major cell subtype; evidence 
of organized architecture; and presence of Tregs. Whereas 
B cells have an initiating role for TLS formation in autoimmune, 
transplantation-related and infectious diseases (24, 25) their 
role in the field of cancer remains to be clarified. Interestingly, 
the major difference between the TLS in MBC and KPs was the 
absence of external capsulae surrounding the tumors and the TLS 
in the mouse model. Lymph node metastasis occurs in 50% of 
the cases in KP mice at late stage, whereas MBC patients are less 
prone to metastasis compared to other breast basal carcinoma 
patients. In  MBC, the presence of the external capsulae might 
protect from local and distant dissemination. In the KP mice, the 
presence of the TLS was associated with enhanced intra-tumor 
apoptosis without enhanced T/B  cell infiltration, suggesting a 
qualitative regulation of intra-tumor lymphocytes related to TLS.
Current knowledge about TLS behavior in the context of 
treatment is inexistent. We hypothesize that MBC would be an 
ideal type of tumor to clinically investigate this question as they 
present strong lymphoplasmocytic infiltration, commonly organ-
ized in TLS; however, the presence of the TLS is not a deciphering 
criterion for any tumor type. The purpose of our study was to 
stimulate this research field by providing a first highlight of 
the interaction between TLS and tumors in the context of RT. 
After RT, the TLS showed an acute increase of apoptosis and 
size reduction. While size tends to normalize after 2 weeks, the 
apoptotic rate remained high, suggesting active and continuous 
proliferation within residual irradiated cells. In order to decipher 
the impact of RT on TLS composition, we used flow cytometry-
based methodology and combined it with sequential examination 
of the composition of the TLS over the course of RT. As B cells are 
mainly found in TLS and granulocytes mainly in tumors, we used 
the B cell/granulocyte ratio as a marker of TLS/tumor abundance. 
We found indeed a significant decrease in the B cell/granulocyte 
ratio at acute time point post-RT consistent with histological 
finding and confirming TLS contribution to immune profile of 
macro-dissected tumors. We reported sequential enrichment 
first in CD8 followed by Foxp3 Tregs in macro-dissected tumors 
post-RT. Interestingly, Foxp3 Tregs enrichment corresponds 
to the restoration phase of the TLS. Consistently, immunosup-
pressive function of specific Tregs located in the TLS has been 
suggested in KP mice (9) and in breast cancer patients with TLS in 
whom FoxP3/T cells were shown to be the only marker associated 
with poor prognosis (12). On the other hand, at late time point 
a highly significant increase in CD103 positive cells among CD8 
was measured, suggesting infiltration with memory T cells (26).
The KP model was first published in 2009 (20) and considered 
as “non-immunogenic” due to its low level of basal infiltrating 
immune cells. It was subsequently modified to express OVA 
peptide and stimulate immune response upon adoptive T  cell 
transplantation, but this strategy only led to minor improvement 
(27). However, a better outcome was obtained with combination 
of chemotherapy and immune checkpoint inhibitors (15) and 
interestingly, this strategy was found to be TLS dependent. More 
recently, Faget et al. described occurrence of TLS in the native KP 
model and achieved an immune-based tumor delay mediated by 
normalization of tumor vasculature, using a granulocytes deplet-
ing antibody in combination with immune checkpoint blockade 
(21). In the meantime, a vascular-based strategy also showed TLS 
occurrence in a pancreatic cancer model, associated with tumor 
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delay (14). This suggests TLS formation or functionality may 
be dependent on vascular quality and may be of importance to 
design combined therapeutic strategy.
In conclusion, we investigated the radiation-induced modi-
fication of TLS composition and tumor immune infiltrate over 
time. Although descriptive, our study provides the first timely 
comprehensive view of TLS modulation occurring in tumors 
associated with TLS after irradiation. In the context of tumors 
associated with TLS, flow cytometry analysis includes immune 
infiltrate coming from both tumors and TLS. The radiation-
induced response is complex. It induces a reset of the TLS followed 
by a rapid restoration associated with Tregs enrichment of the 
global tumor microenvironment. Future experiments are needed 
to enhance the radiation-induced beneficial components as well 
as repress the deleterious ones. More specifically, comparing TLS 
versus lymph node response to radiotherapy would increase 
our understanding of the loco-regional immune response. In 
addition, neoadjuvant irradiation of the breast at lower doses 
in the context of TLS may have immunomodulatory properties 
and enhance systemic immunity. Such strategies should bring 
insights for personalized therapeutic management of tumors 
associated with TLS. In the specific context of MBC where TLS 
are commonly observed, acute manipulation of TLS composition 
using RT combined with immune checkpoint inhibitor prior 
mastectomy could provide long-lasting benefits and be worth 
further clinical investigation.
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